Timeline
Cytospire Therapeutics
London oncology biotech; first-in-class T cell engager drug for solid tumours; £61m Series A May 2026.
3 of 3 entries (3 events, 0 interactions)
Filters
#72 Jun
Mentioned in: IMU raises £40m to read blood
UK Startups and Innovation#513 May
Mentioned in: Lansdowne hits €128.9m on BBB-anchored fund
UK Startups and Innovation#45 May